|
1
|
Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer.
|
J Clin Oncol
|
2007
|
3.65
|
|
2
|
Long-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer: the MGH experience.
|
Eur Urol
|
2011
|
3.17
|
|
3
|
Transurethral surgery and twice-daily radiation plus paclitaxel-cisplatin or fluorouracil-cisplatin with selective bladder preservation and adjuvant chemotherapy for patients with muscle invasive bladder cancer (RTOG 0233): a randomised multicentre phase 2 trial.
|
Lancet Oncol
|
2013
|
2.34
|
|
4
|
Celecoxib versus placebo for men with prostate cancer and a rising serum prostate-specific antigen after radical prostatectomy and/or radiation therapy.
|
J Clin Oncol
|
2006
|
2.29
|
|
5
|
Phase II study of pemetrexed for second-line treatment of transitional cell cancer of the urothelium.
|
J Clin Oncol
|
2006
|
2.09
|
|
6
|
Organ conservation in invasive bladder cancer by transurethral resection, chemotherapy and radiation: results of a urodynamic and quality of life study on long-term survivors.
|
J Urol
|
2003
|
1.74
|
|
7
|
Application of a fracture risk algorithm to men treated with androgen deprivation therapy for prostate cancer.
|
J Urol
|
2010
|
1.66
|
|
8
|
Benchmarks achieved in the delivery of radiation therapy for muscle-invasive bladder cancer.
|
Urol Oncol
|
2007
|
1.44
|
|
9
|
Late pelvic toxicity after bladder-sparing therapy in patients with invasive bladder cancer: RTOG 89-03, 95-06, 97-06, 99-06.
|
J Clin Oncol
|
2009
|
1.35
|
|
10
|
Rosiglitazone versus placebo for men with prostate carcinoma and a rising serum prostate-specific antigen level after radical prostatectomy and/or radiation therapy.
|
Cancer
|
2004
|
1.31
|
|
11
|
RTOG 97-06: initial report of a phase I-II trial of selective bladder conservation using TURBT, twice-daily accelerated irradiation sensitized with cisplatin, and adjuvant MCV combination chemotherapy.
|
Int J Radiat Oncol Biol Phys
|
2003
|
1.26
|
|
12
|
Overview of bladder cancer trials in the Radiation Therapy Oncology Group.
|
Cancer
|
2003
|
1.03
|
|
13
|
Lymphotropic nanoparticle-enhanced magnetic resonance imaging (LNMRI) identifies occult lymph node metastases in prostate cancer patients prior to salvage radiation therapy.
|
Clin Imaging
|
2009
|
0.98
|
|
14
|
Complications and long-term results of salvage cystectomy after failed bladder sparing therapy for muscle invasive bladder cancer.
|
J Urol
|
2011
|
0.95
|
|
15
|
Selective bladder preservation by trimodality therapy for patients with muscularis propria-invasive bladder cancer and who are cystectomy candidates--the Massachusetts General Hospital and Radiation Therapy Oncology Group experiences.
|
Semin Radiat Oncol
|
2005
|
0.91
|
|
16
|
A phase I study of estramustine, weekly docetaxel, and carboplatin chemotherapy in patients with hormone-refractory prostate cancer.
|
Clin Cancer Res
|
2005
|
0.86
|
|
17
|
Randomized phase II study of atrasentan alone or in combination with zoledronic acid in men with metastatic prostate cancer.
|
Cancer
|
2006
|
0.85
|
|
18
|
The results of concurrent chemo-radiotherapy for recurrence after treatment with bacillus Calmette-Guérin for non-muscle-invasive bladder cancer: is immediate cystectomy always necessary?
|
BJU Int
|
2008
|
0.84
|
|
19
|
Bladder preservation: optimizing radiotherapy and integrated treatment strategies.
|
BJU Int
|
2008
|
0.84
|
|
20
|
Nomograms predicting response to therapy and outcomes after bladder-preserving trimodality therapy for muscle-invasive bladder cancer.
|
Int J Radiat Oncol Biol Phys
|
2013
|
0.81
|
|
21
|
Surgery: selective bladder-preserving therapy for muscle-invasive cancer.
|
Nat Rev Clin Oncol
|
2009
|
0.80
|
|
22
|
Male patients with diagnoses of both breast cancer and prostate cancer.
|
Breast J
|
2003
|
0.80
|
|
23
|
Association of statin use with improved local control in patients treated with selective bladder preservation for muscle-invasive bladder cancer.
|
Urology
|
2006
|
0.80
|
|
24
|
Trimodality therapy for bladder conservation in treatment of invasive bladder cancer.
|
Curr Urol Rep
|
2013
|
0.79
|
|
25
|
Bladder-sparing approaches to invasive disease.
|
World J Urol
|
2006
|
0.78
|
|
26
|
Finasteride and flutamide therapy in patients with advanced prostate cancer: response to subsequent castration and long-term follow-up.
|
Urology
|
2003
|
0.78
|
|
27
|
Case records of the Massachusetts General Hospital. Case 6-2006. A 71-year-old woman with urinary incontinence and a mass in the bladder.
|
N Engl J Med
|
2006
|
0.77
|
|
28
|
Immunohistochemistry as an adjunct in the differential diagnosis of radiation-induced atypia versus urothelial carcinoma in situ of the bladder: a study of 45 cases.
|
Hum Pathol
|
2012
|
0.75
|
|
29
|
Case records of the Massachusetts General Hospital. Case 25-2013. A 71-year-old man with hematuria and a mass in the bladder.
|
N Engl J Med
|
2013
|
0.75
|
|
30
|
Pooled analysis of phase II trials evaluating weekly or conventional cisplatin as first-line therapy for advanced urothelial carcinoma.
|
Clin Genitourin Cancer
|
2013
|
0.75
|
|
31
|
Neoadjuvant doxil chemotherapy prior to androgen ablation plus radiotherapy for high-risk localized prostate cancer: feasibility and toxicity.
|
Am J Clin Oncol
|
2003
|
0.75
|
|
32
|
Transitional cell carcinoma of the upper uroepithelial tract.
|
Clin Adv Hematol Oncol
|
2003
|
0.75
|
|
33
|
Case records of the Massachusetts General Hospital. Case 15-2008. A 55-year-old man with an elevated prostate-specific antigen level and early-stage prostate cancer.
|
N Engl J Med
|
2008
|
0.75
|
|
34
|
A phase II trial of interferon-alpha and toremifene in advanced renal cell cancer patients.
|
Cancer Invest
|
2002
|
0.75
|